Intermittent HIV-1 viremia (Blips) and virological failure in a cohort of people living with HIV from São Paulo, Brazil

AIDS Patient Care and STDs

Volumn 26, Issue 9, 2012, Pages 512-515

  Ibrahim, Karim Yaqub ^a   Recordon Pinson, Patricia ^b   Malvy, Denis ^c   Fleury, Hervé ^b   Segurado, Aluisio Cotrim ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HÔPITAL PELLEGRIN   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ILLICIT DRUG; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL CONSUMPTION; BISEXUAL FEMALE; BISEXUAL MALE; BRAZIL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMORBIDITY; DNA POLYMORPHISM; DRUG TREATMENT FAILURE; FOLLOW UP; GENE AMPLIFICATION; GENOTYPE; HEALTH HAZARD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMITTENT VIREMIA; LETTER; PATIENT COMPLIANCE; PHENOTYPE; PROT GENE; SELF REPORT; SEXUAL BEHAVIOR; UNSAFE SEX; VIREMIA; VIROLOGICAL FAILURE; VIRUS DETECTION; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ADULT; BRAZIL; COHORT STUDIES; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; VIRAL LOAD; VIREMIA;

EID: 84865501397     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2012.0199     Document Type: Letter

References (12)

1. Johnson VA, Calvez V, Gü nthard HF, et al. 2011 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2011;19:156-164.
2. Havlir DV, Basset R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001;286:171-179. (Pubitemid 32640848)
3. Sklar PA, Ward DJ, Baker RK, et al and the HIV Outpatients Study (HOPS) Investigators. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002;16:2035-2041. (Pubitemid 35205267)
4. Moore AL, Youle M, Lipman M, et al. Raised viral load in patientswith viral suppression highly active antiretroviral therapy: Transient increase or treatment failure? AIDS 2002;16:615-618. (Pubitemid 34218857)
5. Greub G, Cozzi-Lepri A, Ledergerber B, et al for the Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002;16:1967-1969.
6. Masquelier B, Pereira E, Peytavin G, et al. Intermittent viremia during first-line, protease inhibitors containing therapy: Significance and relationship with drug resistance. J Clin Virol 2005;33:75-78. (Pubitemid 40431581)
7. Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect 2005;51:195-200. (Pubitemid 41554826)
8. Sungkanuparph S, Overton ET, Seyfried W, Groger RK,Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reversetranscriptase inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005;41:1326-1332. (Pubitemid 41532678)
9. Willberg CB, McConnell JJ, Eriksson EM, et al. Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS Pathog 2008;4:1-13.
10. Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect 2003;79:59-61. (Pubitemid 36237829)
11. Kalichman SC, Cherry C, Amaral CM, et al. Adherence to antiretroviral therapy and HIV transmission risks: Implications for test-and-treat approaches to HIV prevention. AIDS Patient Care STDs 2010;24:271-277.
12. Sabino EC, Diaz RS, Brigido LF, et al. Distribution of HIV-1 subtypes seen in an AIDS clinic in Sáo Paulo City, Brazil. AIDS 1996;10:1579-1584(Pubitemid 26370674)